aTyr Pharma, Inc.
ATYR
$5.35
$0.408.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.78% | 3.94% | -1.40% | -52.20% | -32.16% |
| Total Depreciation and Amortization | 1.04% | -50.26% | -100.25% | -60.93% | -34.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10,675.00% | 1,076.12% | 194.74% | 144.76% | 96.68% |
| Change in Net Operating Assets | 197.48% | 79.23% | -53.96% | 223.84% | -26,476.47% |
| Cash from Operations | 32.06% | 31.10% | -18.71% | -37.65% | -70.27% |
| Capital Expenditure | -12.50% | -- | -47.06% | 97.31% | 99.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.86% | -230.10% | -134.02% | 263.58% | 479.28% |
| Cash from Investing | -50.94% | -225.96% | -134.15% | 309.45% | 261.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.13% | -8.26% | -11.30% | -15.74% | -17.14% |
| Issuance of Common Stock | 33.33% | 138.94% | 208.46% | -99.28% | 66.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 33.56% | 140.98% | 212.21% | -103.91% | 67.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,375.39% | 92.43% | -102.96% | 287.77% | 96.06% |